US22663K1079

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

January 04, 2026 16:00 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

3 days ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025 16:41 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

3 months ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025

July 13, 2025 17:45 ET  | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels…

6 months ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 16:28 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

6 months ago